Skip to main content
SpringerLink
Log in
Book cover

PET/MRI in Oncology pp 291–304Cite as

PET/MRI in Neuroendocrine Tumours

  • Chapter
  • First Online:

Abstract

Hybrid PET/MRI scanners allowing whole-body imaging are now available for clinical and research use. This new technology has the potential to combine the exquisite sensitivity and molecular relevance of PET imaging, spatial resolution and soft tissue contrast of MRI and the functional imaging capability of both, to achieve a synergistic effect. The study of PET/MRI and its impact on NET management is still at its infancy. However, the potential of PET/MRI in this setting can be gained from our experience with existing PET radiopharmaceuticals, comparative experience with PET/CT and MRI contrasting their relative merits and the PET/MRI studies to date on this topic.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015;35:92–103.

    Article  Google Scholar 

  2. Klimstra DS. Pathologic classification of neuroendocrine neoplasms. Hematol Oncol Clin North Am. 2016;30:1–19.

    Article  PubMed  Google Scholar 

  3. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  4. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27:273–82.

    Article  CAS  Google Scholar 

  5. Deppen SA, Liu E, Blume JD, et al. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57:708–14.

    Article  CAS  PubMed  Google Scholar 

  6. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875–82.

    Article  CAS  PubMed  Google Scholar 

  7. Schreiter NF, Bartels AM, Froeling V, et al. Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT. Radiol Oncol. 2014;48:339–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103:125–38.

    Article  CAS  PubMed  Google Scholar 

  9. Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153–71.

    Article  CAS  PubMed  Google Scholar 

  10. Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.

    Article  CAS  PubMed  Google Scholar 

  11. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927–32.

    Article  PubMed  Google Scholar 

  12. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55–62.

    Article  CAS  PubMed  Google Scholar 

  14. Ruf J, Schiefer J, Kropf S, et al. Quantification in (68)Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide positron emission tomography/computed tomography: can we be impartial about partial volume effects? Neuroendocrinology. 2013;97:369–74.

    Article  CAS  PubMed  Google Scholar 

  15. Johnbeck CB, Knigge U, Loft A, et al. Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58:451–7.

    Article  CAS  PubMed  Google Scholar 

  16. Fani M, Del Pozzo L, Abiraj K, et al. PET of Somatostatin receptor-positive tumors using 64Cu- and 68Ga-Somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52:1110–8.

    Article  CAS  PubMed  Google Scholar 

  17. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447–55.

    Article  PubMed  Google Scholar 

  18. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.

    Article  CAS  PubMed  Google Scholar 

  19. Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58:91–6.

    Article  PubMed  Google Scholar 

  20. Luo Y, Pan Q, Yao S, et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med. 2016;57:715–20.

    Article  CAS  PubMed  Google Scholar 

  21. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573–86.

    Article  CAS  PubMed  Google Scholar 

  22. Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - imaging and staging. Best Pract Res Clin Endocrinol Metab. 2016;30:45–57.

    Article  PubMed  Google Scholar 

  23. Brabander T, Kwekkeboom DJ, Feelders RA, Brouwers AH, Teunissen JJ. Nuclear medicine imaging of neuroendocrine tumors. Front Horm Res. 2015;44:73–87.

    Article  CAS  PubMed  Google Scholar 

  24. Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850–6.

    Article  PubMed  Google Scholar 

  25. Schreiter NF, Nogami M, Steffen I, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol. 2012;22:458–67.

    Article  PubMed  Google Scholar 

  26. Mayerhoefer ME, Ba-Ssalamah A, Weber M, et al. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol. 2013;23:1978–85.

    Article  PubMed  Google Scholar 

  27. Hope TA, Pampaloni MH, Nakakura E, et al. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015;40:1432–40.

    Article  PubMed  Google Scholar 

  28. Sawicki LM, Deuschl C, Beiderwellen K, et al. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. Eur Radiol. 2017;27(10):4091–9.

    Article  PubMed  Google Scholar 

  29. Tamm EP, Bhosale P, Lee JH, Rohren EM. Sktate-of-the-art imaging of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am. 2016;25:375–400.

    Article  PubMed  PubMed Central  Google Scholar 

  30. De Robertis R, D'Onofrio M, Zamboni G, et al. Pancreatic neuroendocrine neoplasms: clinical value of diffusion-weighted imaging. Neuroendocrinology. 2016;103:758–70.

    Article  PubMed  Google Scholar 

  31. Masselli G, Casciani E, Polettini E, Laghi F, Gualdi G. Magnetic resonance imaging of small bowel neoplasms. Cancer Imaging. 2013;13:92–9.

    PubMed  PubMed Central  Google Scholar 

  32. Dohan A, El Fattach H, Barat M, et al. Neuroendocrine tumors of the small bowel: evaluation with MR-enterography. Clin Imaging. 2016;40:541–7.

    Article  PubMed  Google Scholar 

  33. Beiderwellen K, Kinner S, Gomez B, et al. Hybrid imaging of the bowel using PET/MR enterography: feasibility and first results. Eur J Radiol. 2016;85:414–21.

    Article  PubMed  Google Scholar 

  34. Etchebehere EC, de Oliveira Santos A, Gumz B, et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med. 2014;55:1598–604.

    Article  PubMed  Google Scholar 

  35. Schraml C, Schwenzer NF, Sperling O, et al. Staging of neuroendocrine tumours: comparison of [(6)(8)Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13:63–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Gaertner FC, Beer AJ, Souvatzoglou M, et al. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Investig Radiol. 2013;48:263–72.

    Article  Google Scholar 

  37. Beiderwellen K, Poeppel TD, Hartung-Knemeyer V, et al. Simultaneous 68Ga-DOTATOC PET/MRI in patients with Gastroenteropancreatic neuroendocrine tumors. Investig Radiol. 2013;48:273.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Nuclear Medicine, University College London, London, UK

    Simon Wan & Jamshed Bomanji

Authors
  1. Simon Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jamshed Bomanji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon Wan .

Editor information

Editors and Affiliations

  1. Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA, USA

    Andrei Iagaru

  2. Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA

    Thomas Hope

  3. Dept. of Nuclear Medicine, University of Zurich, Zurich, Switzerland

    Patrick Veit-Haibach

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wan, S., Bomanji, J. (2018). PET/MRI in Neuroendocrine Tumours. In: Iagaru, A., Hope, T., Veit-Haibach, P. (eds) PET/MRI in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-68517-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68517-5_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68516-8

  • Online ISBN: 978-3-319-68517-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation